Arikayce inhaled liposomal amikacin developer Insmed has announced that former AstraZeneca CEO David R. Brennan will join the company’s board of directors.
Insmed Chairman of the Board Donald J. Hayden commented, “We are delighted to welcome David to the Insmed Board. David’s deep and diverse set of global operating experiences will be invaluable as we build Insmed into a global commercial biopharmaceutical company with novel therapies across orphan, pulmonary and infectious diseases.”
Brennan said, “I am excited to join Insmed at this stage in its growth. My personal interests are in companies where the products can make a meaningful difference in treating unmet medical needs. Given their focus on orphan diseases and their most recent clinical data in nontuberculous mycobacteria lung infections, I believe Insmed has a unique opportunity to improve the lives of patients. I look forward to working with the Insmed Board and leadership team to further the company’s strategic objectives to become an industry leader.”
Read the Insmed press release.
